RxDoctor Payments Data

Vaqar Dar, MD

Internal Medicine · Dallas, TXNPI 1184643728

Payments from drug & device makers

$833in general payments, 2019–2025

Across 9 payments — averaging $92.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$250
  • Supernus Pharmaceuticals, Inc.$250
  • Ironshore Pharmaceuticals Inc.$125
  • Avanir Pharmaceuticals, Inc.$112
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$96

What the payments were for

  • Food & beverage$833100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$833 in reported general payments places this provider in the 65th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$242,819
Medicare patients
441
Services billed
2,471

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban556$179,193
XifaxanRifaximin24$43,186
XareltoRivaroxaban128$36,205
JardianceEmpagliflozin84$28,688
MyrbetriqMirabegron64$18,827
NuedextaDextromethorphan Hbr/Quinidine23$17,904
JanuviaSitagliptin Phosphate61$17,500
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$12,748
Pantoprazole Sodium411$11,772
OzempicSemaglutide11$11,300
FarxigaDapagliflozin Propanediol19$10,309
Atorvastatin Calcium687$9,532
Potassium Chloride365$8,781
Levothyroxine Sodium781$7,859
RestasisCyclosporine16$7,194

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Avanir Pharmaceuticals, Inc.Nuedexta$112$17,90423 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →